Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE …
2024年8月29日 · Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with stereotactic body …
「K 药」两项 Ⅲ 期临床试验被终止 - 腾讯网
2024年8月30日 · KEYNOTE-867 是一项随机、双盲 3 期临床试验（NCT03924869），旨在评估帕博利珠单抗联合立体定向放射治疗 (SBRT) 与安慰剂联合 SBRT 治疗无法切除的 I 期或 II …
KEYNOTE-867: Phase 3, Randomized, Placebo-Controlled Study of ...
2022年11月1日 · KEYNOTE-867 (NCT03924869) evaluates the efficacy and safety of SBRT with or without pembrolizumab in patients with unresected stage I or II NSCLC.
Drew Moghanaki: The phase III KEYNOTE-867 study results at …
2024年12月9日 · “The phase III KEYNOTE-867 study results will be presented this week at ESMO24. The difference in G3 toxicity rates is impressive: only 3.7% with lung SBRT …
Meeting Abstract: 2022 ASCO Annual Meeting I - ASCO Publications
KEYNOTE-867 (NCT03924869) evaluates the efficacy and safety of SBRT with or without pembrolizumab in patients with unresected stage I or II NSCLC.
including those with locally advanced inoperable tumors. KEYNOTE-867 (NCT03924869) evaluates the efficacy and safety of SBRT with or without pembrolizumab in patients with …
Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of …
2024年8月29日 · Merck has discontinued the phase 3 KEYNOTE-867 (NCT03924869) and KEYNOTE-630 trials (NCT03833167), according to a press release. KEYNOTE-867 evaluated …
Merck Halts 2 Phase 3 KEYNOTE Studies of Pembrolizumab
2024年8月30日 · KEYNOTE-867 was evaluating pembrolizumab, the anti–PD-1 therapy, in combination with stereotactic body radiotherapy (SBRT) for the treatment of stage I or II …
NSCLC and CSCC Trials Discontinued Due to No Efficacy Benefit …
2024年8月29日 · The phase 3 KEYNOTE-867 and KEYNOTE-630 trials assessing pembrolizumab (Keytruda) plus stereotactic body radiotherapy (SBRT) in patients with stage I …
默沙东K药两项 III 期癌症试验失败！肺癌与皮肤癌疗效不佳
2024年9月2日 · 8月29日，默沙东宣布因疗效不佳停止Keytruda治疗肺癌和皮肤癌的Ⅲ期研究。KEYNOTE-867显示Keytruda+SBRT未能显著改善NSCLC患者生存期，且不良事件发生率高 …